A new light-activated platinum based compound seems to be up to 80 times more powerful in killing cancer cells than other platinum-based anti-cancer drugs. Researchers have found that these compounds use ‘light activation’ to kill cancer cells more specifically than other similar treatments.
A team of researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republic’s Institute of Biophysics has discovered the platinum-based compound known as ‘trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)]’, or a light activated PtIV complex.The compound is highly stable and non-toxic if left in the dark but if light falls upon it becomes much less stable and highly toxic to cancer cells.
It is between 13 and 80 times more toxic (depending on how and on which cells it is used) to cancer cells than the current platinum based anti-cancer drug Cisplatin. Moreover, it kills the cells by a different mechanism of action, so it can also kill cisplatin-resistant cells.
'Light activation provides its massive toxic power and also allows treatment to be targeted much more accurately against cancer cells,' said Professor Peter Sadler, Chairman of the Chemistry Department of the University of Warwick, who led the research project.
The platinum-based compound could be used in particular to treat surface cancers. Patients could be treated in a darkened environment with light directed specifically at cancer cells containing the compound activating the compound’s toxicity and killing those cells.
Normal cells exposed to the compound would be protected by keeping the patient in darkness until the compound has passed through and out of the patient.
Advertisement
Although this work is in its initial stages, the researches are hoping that in a few years time, the new platinum compound could be used in a new type of photoactivated chemotherapy for cancer
Advertisement
KAR/M
